CN104127666A - Pharmaceutical composition for treating xerophthalmia - Google Patents
Pharmaceutical composition for treating xerophthalmia Download PDFInfo
- Publication number
- CN104127666A CN104127666A CN201410338868.2A CN201410338868A CN104127666A CN 104127666 A CN104127666 A CN 104127666A CN 201410338868 A CN201410338868 A CN 201410338868A CN 104127666 A CN104127666 A CN 104127666A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- parts
- xerophthalmia
- flos
- crude drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a pharmaceutical composition for treating xerophthalmia and a preparation method thereof. The pharmaceutical composition is prepared from chrysanthemum, coptis root, radix bupleuri, cordate houttuynia, tuber of dwarf lilyturf, borneol and safflower. The pharmaceutical composition can treat xerophthalmia by fumigating administration. The invention provides the pharmaceutical composition for treating xerophthalmia and the pharmaceutical composition has definite curative effects.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to a kind of pharmaceutical composition for the treatment of xerophthalmia and preparation method thereof.
Background technology
Xerophthalmia refer to tear matter that any reason causes or amount abnormal, or the tear film stability that kinetics causes extremely declines, and with the general name of the various diseases of ophthalmic uncomfortable and (or) eye table organization characteristics of lesion.In treatment, advocate at present taking using artificial tear alleviating dry eye symptom as main individual comprehensive therapy.Traditional Chinese medicine fumigating eyes is applied its thermotherapy, can promote tear circulation, thereby impel lacrimal secretion, and can improve better the nutriture of part tissue of eye, plays the effect of clearing away heat and nourishing YIN dissipating blood stasis.
Summary of the invention
Goal of the invention of the present invention is to provide a kind of new Chinese medicine for the treatment of xerophthalmia and preparation method thereof, to alleviate patient suffering, promotes disease to fully recover as early as possible, has removed patient's sufferings, creates good society and economic benefit.
Drug regimen raw material of the present invention is by weight ratio: Flos Chrysanthemi 180-220 part, Rhizoma Coptidis 130-170 part, Radix Bupleuri 130-170 part, Herba Houttuyniae 130-170 part, Radix Ophiopogonis 140-180 part, Borneolum Syntheticum 110-130 part, Flos Carthami 130-150 part
Preferably: 200 parts of Flos Chrysanthemis, 150 parts of Rhizoma Coptidis, 150 parts of Radix Bupleuri, 150 parts of Herba Houttuyniae, 160 parts of Radix Ophiopogonis, 130 parts of Borneolum Syntheticums, 150 parts, Flos Carthami.
The preparation method of above pharmaceutical composition is: above 7 taste crude drug are mixed, add 5 times of decoctings of crude drug weight and boil 3 times, decoct 2 hours at every turn, filter, merging filtrate, places for subsequent usely, heats fumigation and wash method eyes when use.
The present invention is on Chinese medical theory basis, through a large amount of clinical practice screening gained.Its formula is simple, onset is rapid, evident in efficacy, short treating period, easy to use.
Flos Chrysanthemi: loose wind heat clearing away, suppressing the hyperactive liver improving eyesight.Modern pharmacy studies have shown that, Flos Chrysanthemi has antiviral effect, and foreign study scholar finds, Flos Chrysanthemi has inhibitory action in various degree to herpes simplex virus poliovirus and Measles virus.In addition, also there is the effect such as antiinflammatory, antitumor.
Rhizoma Coptidis: heat clearing and damp drying, eliminating fire and detoxication.Modern pharmacy studies have shown that, the effect such as that Rhizoma Coptidis has is antibacterial, antifungal, antiviral, antiinflammatory, antioxidation.
Radix Bupleuri: induce sweat bring down a fever, dispersing the stagnated live-QI to relieve the stagnation of QI.Modern pharmacy studies have shown that, its composition of Radix Bupleuri mainly contains saikoside, sterol, volatile oil (bupleurumol, eugenol etc.), fatty acid (oleic acid, linoleic acid, Palmic acid, stearic acid etc.) and polysaccharide etc., can be antipyretic, antiinflammatory, antibacterial, Promote immunity function etc.
Herba Houttuyniae: heat-clearing and toxic substances removing, inducing diuresis to remove edema.Modern pharmacy studies have shown that, Herba Houttuyniae has the effects such as enhancing immunity, antibacterial, antiviral, antiinflammatory.
Radix Ophiopogonis: YIN nourishing and the production of body fluid promoting, lung moistening clear away heart-fire.Modern pharmacy studies have shown that, Radix Ophiopogonis is containing multiple steroid saponin, Radix Ophiopogonis Saponin A, B, C, D, glycoside unit is ruscogenin, separately containing ophiopogonin B ', C ', D ', glycoside unit is diosgenin; Still containing multiple flavone compound, as Radix Ophiopogonis methyl flavanone A, B, Radix Ophiopogonis flavanone A, ophiopogonone A, B, methyl ophiopogonone A, B etc., have calmness, improve immunity, fatigue-resisting function.
Borneolum Syntheticum: logical all keys, loose stagnated fire, removing nebula improving eyesight, reducing swelling and alleviating pain.Modern pharmacy studies have shown that, Borneolum Syntheticum contains dextro Borneolum Syntheticum, humulene, beta-elemene, caryophyllene etc., and the triterpenoid such as oleanolic acid, alphitolic acid, asiatic acid, Borneolum Syntheticum are aromatic, erythrodiol.There is good antibacterial, antiinflammatory action.
Flos Carthami: promoting blood circulation to restore menstrual flow, stasis-dispelling and pain-killing.Modern pharmacy studies have shown that, Flos Carthami contains Carthamus yellow, has the effect of good anticoagulation, resisting fatigue, antiinflammatory, raising immunity.
In order to show that medicine of the present invention has therapeutic effect to xerophthalmia, the present invention has carried out following clinical experiment:
1 data and method
1.1 physical data
The object of observation is that in December, 2011～2013 are diagnosed as patients with dry eye in the court year June, is eyes morbidity, totally 64 examples, 128.Wherein male 26 examples, 52; Female's 38 examples, 76; Maximum 65 years old of patient age, minimum 18 years old.64 routine eyes morbidity patients are divided into two groups, treatment group 32 examples, 64 at random; Matched group 32 examples, 64.
1.2 diagnostic criteria
1. main feel symptom: sensation of dryness, foreign body sensation, feeling of fatigue, burn feeling, photophobia, furious, to cigarette, wind, light and air-conditioning sensitivity etc.2. objective sign: Schirmer ' s I test < 10mm/5min; BUT (breakup time of tear film) < 10s.
1.3 Therapeutic Method
Matched group gives the Therapeutic Method of conventional xerophthalmia, gives artificial tears and likes beautiful eye dripping, every day 4 times.Treatment group at conventional using artificial tear simultaneously, is applied after the medicinal liquid of making in medicine embodiment 1 of the present invention dilutes and is added in Siling Medical Equipment Factory, Shanghai's 402 type ultrasound atomizer and heat, with steam fumigating eye, and every day 2 times, each 20min.
1.4 curative effect determinate standard
Cure: subjective symptoms disappears, without conjunctival congestion, Schirmer ' s I test > 15mm, BUT > 15s; Take a turn for the better: subjective symptoms takes a turn for the better, without conjunctival congestion, Schirmer ' s I test > 10mm, BUT > 10s; Invalid: subjective symptoms is without change, conjunctival congestion, Schirmer ' s I test < 10mm, BUT < 10s.
1.5 statistical method
Adopt rank test, P < 0.05 has statistical significance for difference.
2 results
Treatment group curative effect is better than matched group, and difference has statistical significance (P < 0.05), the results are shown in Table 1.
Table 1 liang group curative effect comparison
Note: * P < 0.05, has significant difference
Aspect treatment xerophthalmia, there iing good result by above-mentioned clinical experiment proved invention medicine.
Specific embodiment
Embodiment 1
Flos Chrysanthemi 200g, Rhizoma Coptidis 150g, Radix Bupleuri 150g, Herba Houttuyniae 150g, Radix Ophiopogonis 160g, Borneolum Syntheticum 130g, Flos Carthami 150g.
The preparation method of above pharmaceutical composition is: above 7 taste crude drug are mixed, add 5 times of decoctings of crude drug weight and boil 3 times, decoct 2 hours at every turn, filter, merging filtrate, places for subsequent usely, adds hot smoking eye when use.
Embodiment 2
Flos Chrysanthemi 180g, Rhizoma Coptidis 130g, Radix Bupleuri 170g, Herba Houttuyniae 140g, Radix Ophiopogonis 160g, Borneolum Syntheticum 110g, Flos Carthami 150g.
The preparation method of above pharmaceutical composition is: above 7 taste crude drug are mixed, add 5 times of decoctings of crude drug weight and boil 3 times, decoct 2 hours at every turn, filter, merging filtrate, places for subsequent usely, adds hot smoking eye when use.
Embodiment 3
Flos Chrysanthemi 220g, Rhizoma Coptidis 160g, Radix Bupleuri 150g, Herba Houttuyniae 170g, Radix Ophiopogonis 170g, Borneolum Syntheticum 130g, Flos Carthami 130g.
The preparation method of above pharmaceutical composition is: above 7 taste crude drug are mixed, add 5 times of decoctings of crude drug weight and boil 3 times, decoct 2 hours at every turn, filter, merging filtrate, places for subsequent usely, adds hot smoking eye when use.
Claims (3)
1. treat the pharmaceutical composition of xerophthalmia for one kind, it is characterized in that according to weight portion meter, the raw material of making this pharmaceutical composition active component is: Flos Chrysanthemi 180-220 part, Rhizoma Coptidis 130-170 part, Radix Bupleuri 130-170 part, Herba Houttuyniae 130-170 part, Radix Ophiopogonis 140-180 part, Borneolum Syntheticum 110-130 part, Flos Carthami 130-150 part.
2. a kind of pharmaceutical composition for the treatment of xerophthalmia as claimed in claim 1, it is characterized in that according to weight portion meter, the raw material of making this pharmaceutical composition active component is: 200 parts of Flos Chrysanthemis, 150 parts of Rhizoma Coptidis, 150 parts of Radix Bupleuri, 150 parts of Herba Houttuyniae, 160 parts of Radix Ophiopogonis, 130 parts of Borneolum Syntheticums, 150 parts, Flos Carthami.
3. the preparation method of a kind of pharmaceutical composition for the treatment of xerophthalmia as claimed in claim 1 or 2, it is characterized in that the method is: described 7 taste crude drug are mixed, adding 5 times of decoctings of crude drug weight boils 3 times, each decoction 2 hours, filter, merging filtrate, places for subsequent usely, heats fumigation and wash method eyes when use.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410338868.2A CN104127666A (en) | 2014-07-09 | 2014-07-09 | Pharmaceutical composition for treating xerophthalmia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410338868.2A CN104127666A (en) | 2014-07-09 | 2014-07-09 | Pharmaceutical composition for treating xerophthalmia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104127666A true CN104127666A (en) | 2014-11-05 |
Family
ID=51800688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410338868.2A Pending CN104127666A (en) | 2014-07-09 | 2014-07-09 | Pharmaceutical composition for treating xerophthalmia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104127666A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105125735A (en) * | 2015-08-26 | 2015-12-09 | 周占宇 | Traditional Chinese medicinal composition for treating xerophthalmia |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101843781A (en) * | 2010-05-28 | 2010-09-29 | 郑州市新视明科技工程有限公司 | Chinese medicinal composition for preventing and treating xerophthalmia |
-
2014
- 2014-07-09 CN CN201410338868.2A patent/CN104127666A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101843781A (en) * | 2010-05-28 | 2010-09-29 | 郑州市新视明科技工程有限公司 | Chinese medicinal composition for preventing and treating xerophthalmia |
Non-Patent Citations (5)
| Title |
|---|
| 周婉瑜: "干眼症", 《家庭中医药》 * |
| 彭清华 等: "《全国中医眼科名家学术经验集》", 31 December 2014 * |
| 彭清华，王芬，彭俊: "近年来中医治疗干眼的研究进展", 《中华中医药学刊》 * |
| 李洁，高健生: "鱼腥草雾化治疗干眼病的疗效观察", 《中国实用眼科杂志》 * |
| 李禹，刘骁: "干眼症临床治疗及研究进展", 《中国实用医药》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105125735A (en) * | 2015-08-26 | 2015-12-09 | 周占宇 | Traditional Chinese medicinal composition for treating xerophthalmia |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103735721B (en) | A kind of Chinese medicine treating pink-eye | |
| CN103316141A (en) | Traditional Chinese medicine composition for treating cervical spondylosis | |
| CN103638456B (en) | A kind of Chinese medicine for the treatment of liver cirrhosis and preparation method thereof | |
| CN102579750B (en) | Traditional Chinese medicine composition for treating primary dysmenorrhea | |
| CN102228652B (en) | Chinese medicinal composition for treating chronic peritonitis and preparation method thereof | |
| CN104127666A (en) | Pharmaceutical composition for treating xerophthalmia | |
| CN103860773A (en) | Traditional Chinese medicine composition for treating myocardial ischemia and preparation method thereof | |
| CN102475853A (en) | Tan Fu Kang | |
| CN102406893A (en) | Chinese patent medicine for treating psoriasis. | |
| CN102406865A (en) | Chinese medicinal composition for treating psoriasis | |
| CN105311210A (en) | Pharmaceutical composition for treating rheumatoid bone diseases | |
| CN103800561A (en) | Traditional Chinese medicine for treating renal hematuria | |
| CN102406704B (en) | Chinese medicinal preparation for treating ankylosing spondylitis | |
| CN103211911A (en) | Medicine for treating thromboangiitis obliterans | |
| CN102895529A (en) | Medicine treating apoplexy | |
| CN102579607A (en) | Chinese medicine composition for treating acne | |
| CN103285108B (en) | Chinese medicinal composition treating lumbago | |
| CN101095922A (en) | Chinese traditional medicine composition for treating diabetes peripheral neuritis | |
| CN104306665A (en) | Traditional Chinese medicine ointment for treating scoliosis and preparation method thereof | |
| CN103908560A (en) | Traditional Chinese medicine preparation for treating chicken pox | |
| CN104257967A (en) | Traditional Chinese medicine for treating sports injury | |
| CN102028811B (en) | Traditional Chinese medicine composite used for treating diabetes | |
| CN103908499A (en) | Traditional Chinese medicine ointment for treating infantile chicken pox | |
| CN105288125A (en) | Medicine composition having analgesic effect and preparation method thereof | |
| CN105435112A (en) | Traditional Chinese medicine for quickly treating heart diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141105 |
|
| RJ01 | Rejection of invention patent application after publication |